Status:
COMPLETED
Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes
Lead Sponsor:
Novartis
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This 52-week multicenter open-labeled extension study is designed to assess the long-term safety of vildagliptin (100 mg qd) in patients with Type 2 Diabetes. This extension study is open to patients ...
Eligibility Criteria
Inclusion
- Diagnosis as Type 2 Diabetes
- Patients who have completed study CLAF237A1303
- Outpatients
Exclusion
- Patients who prematurely discontinued Study CLAF237A1303
- Other protocol-defined inclusion/exclusioncriterial may apply
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT00389415
Start Date
October 1 2006
Last Update
November 27 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Tokyo, Japan